| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -2.5 | -3.2 |
| EPS (diluted, $ a share) | $-0.24 | $-5.76 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CNSP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CNS Pharmaceuticals, Inc.: key numbers
- Share price
- $3.48Close, Nov 16
- Market cap
- $5.14M
- Shares outstanding
- 1.48MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CNS Pharmaceuticals, Inc.
All →CNS Pharmaceuticals Shareholder Meeting
CNS Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 30, 2026, where shareholders elected six directors and ratified MaloneBailey, LLP as the independent auditor. Stockholders also approved an amendment to the 2020 Equity Plan to increase the number of authorized shares by 650,000 and approved executive compensation on an advisory basis.